<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043067</url>
  </required_header>
  <id_info>
    <org_study_id>CIDRZ 1226/IRB12-0416</org_study_id>
    <nct_id>NCT02043067</nct_id>
  </id_info>
  <brief_title>Enhanced TB Screening to Determine the Prevalence and Incidence of TB in Patients With HIV</brief_title>
  <official_title>Enhanced TB Screening to Determine the Prevalence and Incidence of TB in a Cohort of HIV Clinic Patients in Lusaka, Zambia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Infectious Disease Research in Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine an enhanced protocol to systematically screen a cohort of 400 new HIV
      clinic enrollees for prevalence and 1-year incidence of tuberculosis (TB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Zambia is a high burden country for both HIV and TB infection and HIV clinic enrollees are a
      high-risk group for active TB. Current Zambian Ministry of Health screening protocols are
      symptom-based even though active case-finding studies in HIV-infected populations have shown
      that symptoms are not always predictive of active TB. As a result, there may be a significant
      amount of un-diagnosed TB among HIV-infected Zambians even in the context of accessing HIV
      care. This study will examine an enhanced protocol to systematically screen a cohort of 400
      new HIV clinic enrollees for prevalence and 1-year incidence of TB using symptoms, light and
      fluorescence microscopy, chest radiography and TB culture of sputum and extra-pulmonary
      fluids (when indicated). In addition, the sensitivity, specificity and cost-effectiveness of
      each diagnostic tool will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of undiagnosed TB in those with HIV.</measure>
    <time_frame>Enrollment screening visit</time_frame>
    <description>Among the cohort of 400 new enrollees at the clinic, all will be tested for TB at the specified time points using enhanced TB screening. Initial diagnosis will use smear microscopy and culture. Chest X-ray will be performed on the second day of enrollment. Presumptive Diagnosis: As culture results will take several days or weeks to become available, a presumptive diagnosis will be made based on history and physical exam, symptoms, smear microscopy and chest radiography results. All patients who are smear-positive by at least one sample will be diagnosed with TB per national guidelines. Patients who are smear-negative or suspected of extra-pulmonary TB based on clinical or radiographic findings may be treated empirically for TB at the discretion of a clinical or medical officer. Sputum samples will also be sent for testing at the end of the study with the Xpert MTB/RIF assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of TB in a cohort of HIV clinic patients screened as 'TB negative'.</measure>
    <time_frame>enrollment, 3, 6, 9 and 12 month visits.</time_frame>
    <description>To account for patients who are censored prior to 12 months of follow-up, the incidence of TB will be calculated as a rate. Each patient will contribute follow-up time until they are censored, are diagnosed with TB, or have been in the study for 12 months. Patients who were diagnosed with TB at enrollment will not be included.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Performance of diagnostic measures</measure>
    <time_frame>Days 1, 2, 3; Months 3, 6 9 and 12</time_frame>
    <description>The performance of symptom screening, light microscopy, fluorescence microscopy, chest x-ray, and Xpert MTB/RIF assay compared to culture of sputum and other fluids in HIV-infected patients will be evaluated using data analysis methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness of each screening/diagnostic tool.</measure>
    <time_frame>Days 1, 2, 3 and months 3, 6, 9 and 12</time_frame>
    <description>The primary outcomes of each diagnostic tool (or combination of diagnostic tools) that will be assessed are: cost per case diagnosed/detected, cost per patient cured, cost per case averted. For instance, the cost per case of active TB detected using the &quot;null&quot; or gold standard screening option will be calculated and compared to the cost per case of active TB detected using each of the other screening options.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical outcomes</measure>
    <time_frame>up to 12 months post-enrollment</time_frame>
    <description>Clinical outcomes will be measured in a cohort of HIV-infected patients and TB/HIV co-infected patients during the first 12 months of HIV care including but not limited to mortality, immune recovery and development of other opportunistic infections.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>new HIV clinic enrollees</arm_group_label>
    <description>All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comprehensive TB screening</intervention_name>
    <description>All enrollees will receive a comprehensive TB screening regardless of symptom presentation.</description>
    <arm_group_label>new HIV clinic enrollees</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Additional samples (10 ml blood, and 20 ml urine) will be stored in the specimen repository
      at the CIDRZ laboratory for future studies. For patients who agree to provide samples for the
      repository and are diagnosed with TB, isolates from positive cultures (blood, urine, and/or
      sputum) will also be stored in the repository.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Four hundred new enrollees at the Kalingalinga HIV Care and Treatment Clinic who are not
        currently being treated for TB.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons with HIV/AIDS, 16 years of age or older, who are enrolling at the Kalingalinga
             ART clinic and are able and willing to provide informed consent

          -  Antiretroviral therapy-na√Øve except for short-course therapy through prevention of
             mother-to-child-transmission programs

          -  Not have taken any TB treatment in the past 3 months

          -  Willing to provide locator information and allow study staff to contact by phone or
             visit them at home if required

        Exclusion Criteria:

          -  Any condition, including active drug or alcohol use, which in the opinion of the
             investigators, would interfere with adherence to study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stewart Reid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIDRZ; University of North Carolina at Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kalingalinga HIV Care and Treatment Clinic</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.unc.edu</url>
    <description>University of North Carolina website</description>
  </link>
  <reference>
    <citation>Harris JB, Hatwiinda SM, Randels KM, Chi BH, Kancheya NG, Jham MA, Samungole KV, Tambatamba BC, Cantrell RA, Levy JW, Kimerling ME, Reid SE. Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia. Int J Tuberc Lung Dis. 2008 Jul;12(7):773-9.</citation>
    <PMID>18544203</PMID>
  </reference>
  <reference>
    <citation>Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, Rutherford G, Mermin J. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007 Mar 30;21(6):713-9.</citation>
    <PMID>17413692</PMID>
  </reference>
  <reference>
    <citation>Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G. Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis. 2004 Jun;8(6):792-5.</citation>
    <PMID>15182152</PMID>
  </reference>
  <reference>
    <citation>Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis. 2006 May;10(5):523-9.</citation>
    <PMID>16704034</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006 Aug 1;20(12):1605-12.</citation>
    <PMID>16868441</PMID>
  </reference>
  <reference>
    <citation>Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker LG. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med. 2007 Jan 1;175(1):87-93. Epub 2006 Sep 14.</citation>
    <PMID>16973982</PMID>
  </reference>
  <reference>
    <citation>Wise J. Southern Africa is moving swiftly to combat the threat of XDR-TB. Bull World Health Organ. 2006 Dec;84(12):924-5.</citation>
    <PMID>17242824</PMID>
  </reference>
  <reference>
    <citation>Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, Small PM. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999 Feb 6;353(9151):444-9. Erratum in: Lancet 1999 May 15;353(9165):1714.</citation>
    <PMID>9989714</PMID>
  </reference>
  <reference>
    <citation>Hern√°ndez-Gardu√±o E, Cook V, Kunimoto D, Elwood RK, Black WA, FitzGerald JM. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax. 2004 Apr;59(4):286-90.</citation>
    <PMID>15047946</PMID>
  </reference>
  <reference>
    <citation>Kimerling ME, Schuchter J, Chanthol E, Kunthy T, Stuer F, Glaziou P, Ee O. Prevalence of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh, Cambodia. Int J Tuberc Lung Dis. 2002 Nov;6(11):988-94.</citation>
    <PMID>12475145</PMID>
  </reference>
  <reference>
    <citation>Ba F, Rieder HL. A comparison of fluorescence microscopy with the Ziehl-Neelsen technique in the examination of sputum for acid-fast bacilli. Int J Tuberc Lung Dis. 1999 Dec;3(12):1101-5.</citation>
    <PMID>10599014</PMID>
  </reference>
  <reference>
    <citation>Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW. HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006 Jun;10(6):663-9.</citation>
    <PMID>16776454</PMID>
  </reference>
  <reference>
    <citation>Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis. 2003 May;3(5):288-96. Review.</citation>
    <PMID>12726978</PMID>
  </reference>
  <reference>
    <citation>Bakari M, Arbeit RD, Mtei L, Lyimo J, Waddell R, Matee M, Cole BF, Tvaroha S, Horsburgh CR, Soini H, Pallangyo K, von Reyn CF. Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis. 2008 Mar 6;8:32. doi: 10.1186/1471-2334-8-32.</citation>
    <PMID>18325120</PMID>
  </reference>
  <reference>
    <citation>Swaminathan S, Paramasivan CN, Kumar SR, Mohan V, Venkatesan P. Unrecognised tuberculosis in HIV-infected patients: sputum culture is a useful tool. Int J Tuberc Lung Dis. 2004 Jul;8(7):896-8.</citation>
    <PMID>15260283</PMID>
  </reference>
  <reference>
    <citation>Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006 Aug 16;296(7):782-93.</citation>
    <PMID>16905784</PMID>
  </reference>
  <reference>
    <citation>Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006 Sep;6(9):570-81. Review. Erratum in: Lancet Infect Dis. 2006 Oct;6(10):628.</citation>
    <PMID>16931408</PMID>
  </reference>
  <reference>
    <citation>Ministry of Health, Human Resources for Health: Strategic Plan 2006-2010. Ministry of Health, Ndeke House, Lusaka. 2006.</citation>
  </reference>
  <reference>
    <citation>Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011 Apr 30;377(9776):1495-505. doi: 10.1016/S0140-6736(11)60438-8. Epub 2011 Apr 18.</citation>
    <PMID>21507477</PMID>
  </reference>
  <reference>
    <citation>Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.</citation>
    <PMID>20825313</PMID>
  </reference>
  <reference>
    <citation>Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, Dawson R, Whitelaw A, Hoelscher M, Sharma S, Pai M, Warren R, Dheda K. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 2011 Jul 1;184(1):132-40. doi: 10.1164/rccm.201101-0056OC. Epub 2011 Apr 14.</citation>
    <PMID>21493734</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005 Jun;5(6):361-73. Review.</citation>
    <PMID>15919622</PMID>
  </reference>
  <reference>
    <citation>Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis. 2006 Sep;10(9):946-53. Review.</citation>
    <PMID>16964782</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and &quot;unmasking&quot; of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008 Apr 1;177(7):680-5. doi: 10.1164/rccm.200709-1311PP. Epub 2008 Jan 17. Review.</citation>
    <PMID>18202347</PMID>
  </reference>
  <reference>
    <citation>Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008 Aug;8(8):516-23. doi: 10.1016/S1473-3099(08)70184-1.</citation>
    <PMID>18652998</PMID>
  </reference>
  <reference>
    <citation>Francis J. Curry National Tuberculosis Center Institutional Consultation Services, Conducting Sputum Induction Safely. 1999.</citation>
  </reference>
  <reference>
    <citation>Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J. 2005 Jun;25(6):1107-16. Review.</citation>
    <PMID>15929967</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TB</keyword>
  <keyword>HIV</keyword>
  <keyword>Extensively resistant TB</keyword>
  <keyword>Extra pulmonary TB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

